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ABSTRACT Cryptococcal epidemiology is shifting toward HIV-negative populations
who have diverse presentations. Cryptococcal antigen (CrAg) testing is also chang-
ing, with development of the lateral flow assay (LFA) having reported increased sen-
sitivity and specificity, but with minimal knowledge in the HIV-negative population.
In this study, we evaluate the real-life performance of CrAg testing in patients with
cryptococcal disease. We conducted a retrospective review of patients with crypto-
coccosis from 2002 to 2019 at Barnes-Jewish Hospital. Latex agglutination (LA) was
used exclusively until April 2016, at which point LFA was used exclusively. Demo-
graphics, presentations, and testing outcomes were evaluated. Serum CrAg testing
was completed in 227 patients with cryptococcosis. Of 141 HIV-negative patients,
107 had LA testing and 34 had LFA testing. In patients with disseminated disease,
serum CrAg sensitivity by LA was 78.1% compared to 82.6% for LFA. In patients with
localized pulmonary disease, serum CrAg sensitivity was 23.5% compared to 90.9%
for LFA. Of 86 people living with HIV (PLWH), 76 had LA testing, and 10 had LFA
testing. Serum CrAg sensitivity for LA was 94.7% compared to 100% for LFA in pa-
tients with disseminated disease. We noted a significant improvement in sensitivity
from LA testing to LFA testing, predominantly in those with localized pulmonary dis-
ease. However, both LFA and LA appear to be less sensitive in HIV-negative patients
than previously described in PLWH.
KEYWORDS Cryptococcus neoformans, cryptococcal antigen, diagnosis, test
performance
Cryptococcosis remains a significant cause of opportunistic infection in people livingwith HIV (PLWH) in the developing world (1); however, the proportion occurring
among HIV-negative patients has been increasing in high-income countries (2–7).
HIV-negative patients have atypical presentations and worse outcomes with crypto-
coccal infection compared to PLWH (2, 7–9). When clinical suspicion exists for crypto-
coccosis, cryptococcal antigen (CrAg) tests are the most rapid and widely used diag-
nostic modality (10–13).
For decades, latex agglutination (LA) has been the mainstay of CrAg testing.
However, over the past decade, the new lateral flow assay (LFA) showed improved
sensitivity and specificity over the LA (14–18). These studies focused on PLWH, almost
exclusively in sub-Saharan Africa, who have higher fungal burdens (14, 16, 19). Com-
bined testing of the LFA and LA suggests that CrAg testing appears to have less
favorable characteristics in the HIV-negative population (20). One recent study com-
pared LA to LFA on serum and cerebrospinal fluid (CSF) samples of 31 HIV-negative
patients, and found that a significant lower limit of detection was required for the LFA,
which improved its sensitivity (15). However, this study has limited generalizability due
to the use of a highly select population that does not represent a true sample of
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cryptococcosis patients (15). To our knowledge, no other systematic studies exist in the
HIV-negative population.
In previous work with our cryptococcal cohort, we have shown that our population
resembles the national trend of an increasing proportion of transplant recipients and
non-HIV nontransplant patients with cryptococcosis (7). In this study, we assess the sensi-
tivity of serum CrAg testing using LA and LFA in a wide population of patients with
cryptococcosis.
MATERIALS AND METHODS
Cohort construction. All patients diagnosed with cryptococcosis at Barnes-Jewish Hospital in St. Louis,
Missouri from 1 January 2002 to 1 March 2019 were reviewed. Cryptococcal infection was defined as positive
serum or CSF CrAg, isolation of Cryptococcus neoformans in culture, or identification by the International
Classification of Diseases (ICD) 9th (117.5, 321.0) or 10th (B45.1-B45.9) editions. Resulting date of the
diagnostic specimen was used as time of diagnosis. All cases were reviewed by two investigators to confirm
accurate diagnosis, and to ensure that all patients had either a proven or probable diagnosis, which served
as the gold standard against which the testing was compared. Only patients with available CrAg results were
included in our analyses and all CrAg testing was collected within 1 week of diagnosis. Patients were then
divided into PLWH and HIV-negative, and further by the type of test performed and by disseminated versus
localized disease, to adequately assess test performance.
Disseminated disease was defined as cryptococcosis occurring outside the lungs (i.e., central nervous
system, skin, liver, etc). Localized pulmonary cryptococcosis was defined as cryptococcal infection limited
to the lungs. Positive CrAg in the serum without any other evidence of dissemination was still classified
as localized disease. Central nervous system infection was defined as a positive CSF CrAg or CSF culture
growing Cryptococcus neoformans. No isolates of Cryptococcus gattii were identified and other species
were excluded. Bloodstream infections were defined as a blood culture positive for Cryptococcus
neoformans.
Patient demographics, laboratory testing, treatment data, and outcomes were abstracted from the
medical chart and evaluated. All CrAg testing from 1 January 2002 through 31 March 2016 was
performed using LA. All CrAg testing from 1 April 2016 through 1 March 2019 was completed exclusively
using the LFA (IMMY, Norman, OK, USA).
Statistical analysis. Categorical variables were analyzed using the Fisher’s exact test and the
chi-square test, as appropriate. Continuous variables were analyzed using the t test and the Mann-
Whitney U test if assumption of normality was violated. P values of 0.05 were considered statistically
significant. Analysis was performed using SPSS [V25] (IBM, Armonk, NY, USA).
RESULTS
Cohort. We reviewed 337 patients who met the definition of cryptococcosis from 1
January 2002 until the end of the study period on 1 March 2019, of which 223 were
HIV-negative patients and 114 PLWH. One hundred seven patients were excluded who
did not have serum CrAg testing done, and an additional three patients were excluded
for receiving the majority of their care outside the Barnes-Jewish network. The remain-
ing 227 patients, of which 141 were HIV-negative patients and 86 PLWH, were included
in our analysis.
In HIV-negative patients, 96 (68.1%) had disseminated disease and 45 (31.9%) had
localized pulmonary disease. Of those with disseminated disease, 20 (20.8%) had negative
serum CrAgs, while of those with localized pulmonary disease, 27 (60%) had negative
serum CrAgs. In disseminated disease, LA was positive in 78.1% of cases and LFA was
positive in 82.6%. For localized pulmonary disease, LA was positive in 23.5% of cases and
90.9% positive for LFA testing (Fig. 1A).
In PLWH, 85 (98.8%) had disseminated disease and 1 (1.2%) had localized pulmonary
disease. Of the 85 patients with disseminated disease, 4 (4.7%) were negative by CrAg
testing, while the one patient with localized disease had a positive CrAg by LA. In
disseminated disease, LA was positive in 94.7% of cases (71 of 75 patients) compared
to LFA, which was positive in 100% of cases (10 of 10) (Fig. 1B).
False negatives were seen in a variety of clinical presentations, including meningitis,
bloodstream infections, and localized pulmonary disease (data not shown), and there
were no specific differences in comorbidities or immune function for this group. Of the
four false negatives with disseminated disease and LFA testing, two had end-stage liver
disease, and of the three bloodstream infection patients with false-negative results, one
had a history of end-stage liver disease and another had a history of liver transplant.
There were no significant differences in the site of cryptococcal infection, nor
differences in patient comorbidities associated with antigen negativity in PLWH or
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HIV-negative patients (Table 1; see also Tables S1 and S2 in the supplemental material).
No differences were seen in 90-day mortality when comparing CrAg positivity, nor
when comparing time to diagnosis or time to initiation of antifungals. In HIV-negative
patients with disseminated disease, patients with negative serum CrAgs (n  5, 25%)
were more likely to have no treatment compared to those with positive serum CrAgs
(n  1, 1.3%) (P  0.001).
In HIV-negative patients with localized pulmonary disease (n  45), patients positive
for CrAg also had similar sites of infection and comorbidities as those that were
negative. Time to initiation of antifungals from admission date was significantly longer
in those with negative serum CrAgs (median 13 days, interquartile range [IQR] 4 to 26)
compared to those with positive serum CrAgs (median 3 days, IQR 2 to 7) (P  0.042)
(Table S2). Rates of treatment were similar based on CrAg positivity, although those
with negative serum CrAgs were numerically less likely to receive liposomal ampho-
tericin B for induction therapy (n  2, 7.4%) compared to those with positive CrAgs
(n  7, 38.9%) (P  0.598), although the numbers are small.
Latex agglutination. We included 183 patients who had LA testing. Of these, 148
had disseminated disease and 35 had localized pulmonary disease. The overall sensi-
tivity of LA was 74.9% (137 of 183). Within disseminated disease, 128 of 148 patients
receiving LA testing were CrAg positive (86.5%). Within localized pulmonary disease,
only 9 of 35 patients receiving LA testing were CrAg positive (25.7%).
Comparing HIV-negative patients to PLWH, 107 of 141 HIV-negative patients had LA
testing versus 76 of 86 PLWH. The overall sensitivity of LA in HIV-negative patients was
FIG 1 CONSORT diagram of 337 patients by their HIV status, dissemination and type of cryptococcal antigen test
performed (2002 to 2019). Among the 223 HIV-negative (A) and 111 PLWH (B) diagnosed with cryptococcal disease
by their dissemination status, the lateral flow assay appears to have a higher sensitivity, especially among
HIV-negative patients and localized disease. LFA, lateral flow assay; LA, latex agglutination; CrAg, serum crypto-
coccal antigen; HIV, human immunodeficiency virus; PLWH, people living with HIV.
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60.7% (65 of 107 patients). In HIV-negative patients, sensitivity of LA in disseminated
disease was 78.1% (57 of 73 patients) and the sensitivity of LA in localized pulmonary
patients was 23.5% (8 of 34 patients) (Tables 2 and 3). In PLWH, the sensitivity of LA in
disseminated disease was 94.7% (71 of 75 patients) and the sensitivity of LA in localized
pulmonary disease was 100% (1 of 1 patient) (Table 3).
Lateral flow assay. We included 44 patients who had LFA testing. Of these, 33
(75%) had disseminated disease and 11 (25%) had localized pulmonary disease. The
overall sensitivity of LFA testing was 88.6% (39 of 44 patients) compared to the overall
sensitivity of LA of 74.9% (P  0.055). Among those with disseminated disease, 29 of 33
patients (87.9%) had a positive LFA test, comparable to 86.5% of those having a positive
LA test (P  0.901). In patients with localized pulmonary disease, 90.9% (10 of 11
patients) had a positive LFA test compared to 25.7% positivity with LA (P  0.001).
Comparing HIV-negative patients to PLWH, the overall sensitivity for LFA in HIV-
negative patients was 85.3% (29 of 34 patients) compared to 100% in PLWH (10 of 10
patients). In HIV-negative patients, sensitivity of LFA in disseminated disease was 82.6%
(19 of 23 patients) and the sensitivity in localized pulmonary disease was 90.9% (10 of
11 patients) (Table 3).
In our cohort, there appeared to be a trend toward a decrease in time to antifungal
initiation in patients with cryptococcal disease when LFA testing was used (1 day versus
3 days, P  0.058) (Table 2).
DISCUSSION
With the changing epidemiology of cryptococcosis (7, 20, 21) and with HIV-negative
patients facing higher mortality, possibly associated with delays in diagnosis due to low
TABLE 1 Baseline characteristics of HIV-negative individuals with disseminated cryptococcosis by positivity of serum cryptococcal antigen
testing 2002 to 2019 (n  96)
Variablea Positive serum CrAg (n  76) Negative serum CrAg (n  20) P value
No. male (%) 52 (68) 12 (60) 0.477
Age in years (median, IQR) 58 (49, 68) 54 (42, 63) 0.144
No. African American (%) 8 (11) 3 (15) 0.758
No. transplant recipients (%) 20 (26) 7 (35) 0.442
No. by site of infection (%)
Pulmonary 14 (18) 5 (25) 0.511
CNS disease 46 (61) 12 (60) 0.966
Bloodstream 45 (59) 8 (40) 0.124
Other site of infection 12 (16) 3 (15) 0.931
No. immunocompetent (%) 15 (20) 7 (35) 0.148
No. with 90-day mortality (%) 28 (37) 5 (25) 0.286
Median days to diagnosis from symptom onset (IQR) 20.5 (7, 34) 18 (5, 24) 0.511
Median days to initiation of antifungals from symptom onset (IQR) 20 (7, 35) 18 (5, 24) 0.561
Median days to initiation of antifungals from admission date (IQR) 3 (1,7) 1 (0, 7) 0.309
aIQR, interquartile range; CNS, central nervous system; CrAg, cryptococcal antigen.
TABLE 2 Baseline characteristics of HIV-negative individuals with disseminated cryptococcosis by type of test performed (n  96)
Variablea Latex agglutination (n  73) Lateral flow assay (n  23) P value
No. male (%) 49 (67) 15 (65) 0.866
Age in years (median, IQR) 56 (45, 67) 61 (53, 69) 0.234
No. African American (%) 8 (11) 3 (13) 0.324
No. transplant recipients (%) 19 (26) 8 (35) 0.415
No. by site of infection (%)
Pulmonary 15 (21) 4 (17) 0.740
CNS disease 42 (58) 16 (70) 0.304
Bloodstream 43 (59) 10 (43) 0.195
Other site of infection 11 (15) 4 (17) 0.789
No. immunocompetent (%) 19 (26) 3 (13) 0.196
No. with 90-day mortality (%) 21 (29) 12 (52) 0.048
Median days to diagnosis from symptom onset (IQR) 19 (7, 34) 20 (7, 34) 0.664
Median days to initiation of antifungals from symptom onset (IQR) 19 (7, 32) 21 (7, 38) 0.753
Median days to initiation of antifungals from admission date (IQR) 3 (0, 7) 1 (0, 5) 0.058
aIQR, interquartile range; CNS, central nervous system; CrAg, cryptococcal antigen.
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clinical suspicion, it is important that these delays are minimized to ensure prompt
treatment initiation. False-negative CrAg tests have been linked to delays in diagnosis,
and HIV-negative patients are more likely to have false-negative serum CrAg testing
given lower fungal burdens compared to PLWH (20). Our study is unique from previous
studies in that we included all cryptococcosis cases, consistent with cohorts likely to be
seen in other academic centers (22). Therefore, it likely represents a cohort that is more
representative of cryptococcosis in the United States. Additionally, disseminated and
localized disease were analyzed separately, and we intentionally separated LA from LFA
testing to compared their performance (20).
Previous work has reported serum CrAg by LFA test sensitivity to be between 97.0
and 100% and specificity between 99.0 and 100%, but this literature does not focus on
HIV-negative populations (14, 17, 19, 23). Our overall LFA sensitivity of 88.6% (95%
confidence interval [CI] 74.6 to 95.7%) was lower than what has been previously
reported, but this is the first real-life analysis of the performance of the assay in this
patient population. In our HIV-negative group with disseminated disease, serum CrAg
sensitivity with LFA was 82.6%, a slight improvement over the LA sensitivity of 78.1%
(Fig. 1A and Table 3). However, the most substantial finding of our study was the
improvement in serum CrAg sensitivity within localized pulmonary disease, from 23.5%
with LA to 90.9% with LFA (Fig. 1A and Table 3).
LA performance in serum samples of PLWH has been reported to have a sensitivity
of between 83 and 100% and a specificity of between 93 and 100% (24, 25). The new
LFA CrAg test has shown promising results, especially in PLWH (14). In a review by
Nalintya, Kiggundu, and Meya, median serum LFA sensitivity was 100% (IQR 95.6%,
100%) and median specificity was 99.5% (IQR 95.7%, 100%) (14). There appeared to be
a modest improvement in PLWH with disseminated disease in our cohort, 94.7% to
100%; however, the numbers for the LFA group are too small to confidently estimate
that this was not due to chance alone.
Overall, CrAg positivity was higher in our cohort’s PLWH compared to HIV-negative
patients. This is consistent with previous studies and possibly due to increased fungal
burden in PLWH (18). This could also be due to the prozone or the postzone effect (26,
27), but this should have also then occurred in the PLWH (27). However, the improve-
ments in the HIV-negative population were predominantly in the diagnosis of localized
disease. This suggests there may be opportunities to further optimize performance of
this assay for HIV-negative patients with disseminated disease.
Previous studies have shown higher sensitivities for LFA compared to LA in cryptococ-
cosis; however, they were limited by a lower heterogeneity in the presentation of crypto-
coccosis (15). We noted that the most significant improvement in sensitivity from LA to LFA
was in those with localized pulmonary disease. This finding is clinically important because
localized disease is shown to be more common among patients without HIV (5), and given
the evolving epidemiology of cryptococcosis in HIV-negative populations, we can expect
that the proportion of atypical presentations will continue to increase.
In our study, patients with positive CrAg testing had shorter times to administration
of antifungals. We also noted significant differences in treatment regimens depending
on CrAg positivity in HIV-negative patients. For those with disseminated disease,
patients with a negative LA test were significantly more likely to receive no treatment
for their cryptococcosis. Patients with localized pulmonary disease were also signifi-
cantly more likely to receive liposomal amphotericin B induction if they had a positive
TABLE 3 Cryptococcal antigen test sensitivity by disease presentation and HIV statusa
Infection type Population % LA sensitivity (95% CI) % LFA sensitivity (95% CI) P value
Localized pulmonary PLWH 100 (0–100) — —
HIV-negative 23.5 (10.8–41.2) 90.9 (58.7–99.8) 0.001
Disseminated PLWH 94.7 (86.9–98.5) 100 (65.1–100) 0.517
HIV-negative 78.1 (66.9–86.9) 82.6 (61.2–95.1) 0.641
aPLWH, people living with HIV; LA, latex agglutination; LFA, lateral flow assay; CI, confidence interval; —, not applicable.
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serum CrAg. In a previous study, we noted delays in diagnosis in non-HIV, nontrans-
plant patients compared to PLWH (7). While there did not appear to be delays in
diagnosis, in HIV-negative patients with localized pulmonary disease, those with neg-
ative serum CrAgs had a significantly longer median time to the initiation of antifungals
compared to those with positive serum CrAgs.
In our HIV-negative group, there were false-negative CrAgs in cryptococcal menin-
gitis and bloodstream infections, as well as localized pulmonary infections. There did
not appear to be any specific difference in their comorbidities or immune function.
However, of the four disseminated-disease patients with negative LFA tests, two had
end-stage liver disease, and of the three bloodstream patients with negative CrAgs, one
had a history of end-stage liver disease and the other had a history of liver transplant.
Patients with cirrhosis are already known to have more severe cryptococcal disease and
poorer outcomes (9). A possible explanation for the false-negative CrAgs in the setting
of bloodstream infection is the postzone phenomenon. This effect has been noted in
other infections conditions, such as syphilis. This effect has been described for both LA
and LFA serum CrAgs (26, 28).
Limitations of this study include being performed at a single, Midwest academic
tertiary care center, which may limit generalizability. This study is also retrospective and
data can be limited by missing records and documentation. We are also limited by a
relatively small number of patients who had LFA tests given the recent change to this
test at our institution. Specificity for the CrAg tests could not be calculated as only
patients with cryptococcosis were included with no control population; however,
specificity of these tests appears to be excellent (17, 18). We are also limited in that
some cases of cryptococcosis were diagnosed solely by positive CrAg test and com-
patible syndrome, therefore there are likely missed diagnoses in patients with negative
cultures who had false-negative CrAgs.
In conclusion, we saw an improvement in sensitivity with serum LFA compared to
LA in both HIV-negative patients and PLWH with cryptococcosis, especially in those
with localized pulmonary disease. While we did not reach sensitivities previously cited,
this may be due to the relatively small size of our LFA cohort, but the previously cited
works have predominantly studied only PLWH and other select populations that may
not be representative of cryptococcosis in the United States. LA tests should not be
used to rule out cryptococcosis, especially in isolated pulmonary and even in those with
disseminated disease. While LFA has higher a higher sensitivity, there were still cases of
false-negatives in some of our HIV-negative patients.
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